The appliance from Lykos — a drug corporation incubated because of the Multidisciplinary Association for Psychedelic Reports, or MAPS — arrived on the FDA less than a cloud of controversy. Former trial contributors experienced alleged adverse events were not documented — which includes inner thoughts of suicidality after the therapy — and t